Advice
following an abbreviated submission
alendronic acid effervescent tablets (Binosto®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of postmenopausal osteoporosis.
SMC restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.
Alendronic acid 70mg effervescent tablets have demonstrated bioequivalence to alendronic acid 70mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets. It is more expensive than generic alendronic acid tablets but is similar to the cost of existing oral solutions.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- alendronic acid (Binosto)
- SMC ID:
- 1137/16
- Indication:
- for the treatment of postmenopausal osteoporosis. Binosto 70 mg reduces the risk of vertebral and hip fractures.
- Pharmaceutical company
- Internis Pharmaceuticals Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 April 2016